Spots Global Cancer Trial Database for Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
Official Title: START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial
Study ID: NCT00990860
Conditions
Study Description
Brief Summary: TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology. This explains the strong scientific rationale for exploring the role of anti-angiogenic therapy such as sorafenib to remedy and strengthen the therapeutic efficacy of TACE to combat liver cancers. Sorafenib plays a prominent auxiliary role by further suppressing the tumor growth and prolonging the time to recurrence and progression. Performing TACE under sorafenib administration may have synergic effect on hepatic tumoral lesions.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
E-Da hospital, Kaohsiung, , Taiwan
Veterans General Hospital- Kaochiung, Kaoshiung, , Taiwan
Veterans General Hospital- Taichung, Taichung, , Taiwan
National Cheng Kung University Hospital, Tainan, , Taiwan
Mackay Memorial Hospital, Taipei, , Taiwan
Tri- Service General Hospital, Taipei, , Taiwan
Veterans General Hospital- Taipei, Taipei, , Taiwan
Chang-Gung Memorial Hospital- LinKou, TaoYuan Hsien, , Taiwan
Contact Details
Name: Yee Chao
Affiliation: VGH-TPE
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
